Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients
Background. Determining preferences regarding the benefits of adjuvant chemotherapy (AC) for stage I GC is critical. Methods. We retrospectively reviewed 1069 patients with pathologically confirmed stage I GC who underwent R0 gastrectomy between 2006 and 2014. Univariate and multivariate survival an...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2018/3249436 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550266809876480 |
|---|---|
| author | Jun Lu Long-long Cao Ping Li Jian-wei Xie Jia-bin Wang Jian-xian Lin Qi-yue Chen Mi Lin Ru-hong Tu Chang-ming Huang Chao-hui Zheng |
| author_facet | Jun Lu Long-long Cao Ping Li Jian-wei Xie Jia-bin Wang Jian-xian Lin Qi-yue Chen Mi Lin Ru-hong Tu Chang-ming Huang Chao-hui Zheng |
| author_sort | Jun Lu |
| collection | DOAJ |
| description | Background. Determining preferences regarding the benefits of adjuvant chemotherapy (AC) for stage I GC is critical. Methods. We retrospectively reviewed 1069 patients with pathologically confirmed stage I GC who underwent R0 gastrectomy between 2006 and 2014. Univariate and multivariate survival analyses were conducted. Systemic inflammation factors were used to develop a scoring system for predicting AC benefits. Results. With a median follow-up of 47 months (range 3–113 months), the 5-year overall survival (OS) rate was 90.5%. The patient score was 1 for either a pretreatment hypoalbuminemia or elevated derived neutrophil-lymphocyte ratio (dNLR) and was 0 otherwise. The SIS served as an independent prognostic factor for reduced OS. AC was delivered to 13.5% (144/1069) of all patients. Compared to surgery alone, AC had no significant effect on survival in both the entire cohort and the IA/IB subgroup. However, in the high-risk group (SIS = 2), patients with AC had a significantly better OS than those undergoing surgery alone. Conclusions. Patients with SIS = 2 may benefit from AC and thus may be considered candidates for adjuvant treatment. However, to confirm our findings, future prospective studies are warranted. |
| format | Article |
| id | doaj-art-3b664a5b7aa845c0ac20adc02344fc23 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-3b664a5b7aa845c0ac20adc02344fc232025-02-03T06:07:07ZengWileyGastroenterology Research and Practice1687-61211687-630X2018-01-01201810.1155/2018/32494363249436Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer PatientsJun Lu0Long-long Cao1Ping Li2Jian-wei Xie3Jia-bin Wang4Jian-xian Lin5Qi-yue Chen6Mi Lin7Ru-hong Tu8Chang-ming Huang9Chao-hui Zheng10Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, ChinaBackground. Determining preferences regarding the benefits of adjuvant chemotherapy (AC) for stage I GC is critical. Methods. We retrospectively reviewed 1069 patients with pathologically confirmed stage I GC who underwent R0 gastrectomy between 2006 and 2014. Univariate and multivariate survival analyses were conducted. Systemic inflammation factors were used to develop a scoring system for predicting AC benefits. Results. With a median follow-up of 47 months (range 3–113 months), the 5-year overall survival (OS) rate was 90.5%. The patient score was 1 for either a pretreatment hypoalbuminemia or elevated derived neutrophil-lymphocyte ratio (dNLR) and was 0 otherwise. The SIS served as an independent prognostic factor for reduced OS. AC was delivered to 13.5% (144/1069) of all patients. Compared to surgery alone, AC had no significant effect on survival in both the entire cohort and the IA/IB subgroup. However, in the high-risk group (SIS = 2), patients with AC had a significantly better OS than those undergoing surgery alone. Conclusions. Patients with SIS = 2 may benefit from AC and thus may be considered candidates for adjuvant treatment. However, to confirm our findings, future prospective studies are warranted.http://dx.doi.org/10.1155/2018/3249436 |
| spellingShingle | Jun Lu Long-long Cao Ping Li Jian-wei Xie Jia-bin Wang Jian-xian Lin Qi-yue Chen Mi Lin Ru-hong Tu Chang-ming Huang Chao-hui Zheng Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients Gastroenterology Research and Practice |
| title | Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients |
| title_full | Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients |
| title_fullStr | Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients |
| title_full_unstemmed | Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients |
| title_short | Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients |
| title_sort | significance of preoperative systemic immune score for stage i gastric cancer patients |
| url | http://dx.doi.org/10.1155/2018/3249436 |
| work_keys_str_mv | AT junlu significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT longlongcao significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT pingli significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT jianweixie significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT jiabinwang significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT jianxianlin significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT qiyuechen significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT milin significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT ruhongtu significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT changminghuang significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients AT chaohuizheng significanceofpreoperativesystemicimmunescoreforstageigastriccancerpatients |